Semorinemab
Alzheimer's Disease
Phase 2Partnered with Genentech
Key Facts
About AC Immune
Founded in 2003 and publicly listed on NASDAQ, AC Immune is a global leader in developing precision diagnostics and therapeutics for neurodegenerative diseases. Its strategy is validated by high-value partnerships with pharmaceutical giants like Takeda, Eli Lilly, and Janssen, which have generated over CHF 450 million in funding. The company is advancing a broad pipeline focused on pathological proteins such as Abeta, Tau, alpha-synuclein, and TDP-43, aiming to slow or prevent disease progression.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |